---
id: 5220
---

# General

## Bibliographic Source(s)

- Elit L, Oliver T, Covens A, Kwon J, Fung-Kee-Fung M, Hirte H, Oza A, Gynecology Cancer Disease Site Group. The role of intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2006 Aug 3. 23 p. (Evidence-based series; no. 4-21). [26 references]

# Identifying Information and Availability

## Bibliographic Source(s)

- Elit L, Oliver T, Covens A, Kwon J, Fung-Kee-Fung M, Hirte H, Oza A, Gynecology Cancer Disease Site Group. The role of intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2006 Aug 3. 23 p. (Evidence-based series; no. 4-21). [26 references]

# Disclaimer

## NGC Disclaimer

The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the [NGC Inclusion Criteria](/help-and-about/summaries/inclusion-criteria).

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

